These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 18953743

  • 1. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment.
    Kurosaki M, Saegert W, Abe T, Lüdecke DK.
    Neurol Res; 2008 Jun; 30(5):518-22. PubMed ID: 18953743
    [Abstract] [Full Text] [Related]

  • 2. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A, Sanno N, Tahara S, Osamura YR.
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [Abstract] [Full Text] [Related]

  • 3. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
    Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K.
    Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
    [Abstract] [Full Text] [Related]

  • 4. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S.
    Endocr J; 2015 Dec; 62(1):21-7. PubMed ID: 25273395
    [Abstract] [Full Text] [Related]

  • 5. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
    Lundin P, Edén Engström B, Karlsson FA, Burman P.
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
    [Abstract] [Full Text] [Related]

  • 6. Morphological effects of octreotide on growth hormone-producing pituitary adenomas.
    Ezzat S, Horvath E, Harris AG, Kovacs K.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):113-8. PubMed ID: 8027215
    [Abstract] [Full Text] [Related]

  • 7. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW.
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [Abstract] [Full Text] [Related]

  • 11. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
    Abe T, Lüdecke DK.
    Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
    [Abstract] [Full Text] [Related]

  • 12. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 13. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 15. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 16. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas.
    Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E.
    J Endocrinol Invest; 2003 Jan; 26(1):23-8. PubMed ID: 12602530
    [Abstract] [Full Text] [Related]

  • 17. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
    Hofland LJ, Velkeniers B, vd Lely AJ, van Koetsveld PM, Kazemzadeh M, Waaijers M, Hooghe-Peters EL, Lamberts SW.
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
    [Abstract] [Full Text] [Related]

  • 18. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW.
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [Abstract] [Full Text] [Related]

  • 19. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
    Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U.
    J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
    [Abstract] [Full Text] [Related]

  • 20. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K.
    Endokrynol Pol; 2010 Oct; 61(2):178-81. PubMed ID: 20464704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.